A61K 38/30
Insulin-like growth factors, i.e. somatomedins
Official title: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
A61K38/30 (Insulin-like growth factors, i.e. somatomedins) appears on 557 US grants and 852 published applications in this corpus.
Search patents in A61K- Granted patents
- 557
- Published applications
- 852
- Assignees
- 435
- Inventors
- 1,397
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 7 | 0 |
| 1992 | 7 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 8 | 0 |
| 1996 | 9 | 0 |
| 1997 | 31 | 0 |
| 1998 | 21 | 0 |
| 1999 | 19 | 0 |
| 2000 | 20 | 0 |
| 2001 | 13 | 2 |
| 2002 | 14 | 25 |
| 2003 | 17 | 44 |
| 2004 | 19 | 34 |
| 2005 | 10 | 22 |
| 2006 | 13 | 40 |
| 2007 | 12 | 35 |
| 2008 | 11 | 42 |
| 2009 | 12 | 34 |
| 2010 | 16 | 37 |
| 2011 | 14 | 39 |
| 2012 | 27 | 46 |
| 2013 | 18 | 32 |
| 2014 | 27 | 60 |
| 2015 | 20 | 38 |
| 2016 | 26 | 30 |
| 2017 | 31 | 26 |
| 2018 | 16 | 33 |
| 2019 | 20 | 31 |
| 2020 | 18 | 31 |
| 2021 | 16 | 26 |
| 2022 | 10 | 27 |
| 2023 | 9 | 31 |
| 2024 | 10 | 32 |
| 2025 | 17 | 34 |
| 2026 | 7 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition and methods of treatment for skin health and sleep quality using synergistically-enhanced supplementation22 Sep 2026US 12,741,004 B2Xygenyx Inc.
- Methods of treatment of a cytokine storm25 Aug 2026US 12,714,721 B2Loma Linda University Health
- Methods and compositions for treating chronic lung diseases14 Jul 2026US 12,678,482 B2Oak Hill Bio Limited
- Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues16 Jun 2026US 12,653,899 B2Massachusetts Institute of Technology
- Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase17 Mar 2026US 12,576,138 B2Julius-Maximilians-UniversitäT WüRzburg
- Neurotrauma treatment1 Oct 2026US 2026/0295016 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Combination therapy for preterm infants27 Aug 2026US 2026/0248894 A1
- Modulating Neuroinflammation6 Aug 2026US 2026/0224662 A1Massachusetts Eye and Ear Infirmary
- Methods of treatment using igf-1 chimeric proteins6 Aug 2026US 2026/0226132 A1Silver Creek Pharmaceuticals, Inc.
- Methods for Bicameral, CNS+ Treatment of CNS, Cardiovascular, Metabolic and Other Disorders23 Jul 2026US 2026/0207714 A1
Most cited
By later US patents
- Compositions and therapeutic methods using morphogenic proteins and stimulatory factors265US 5,948,428 AStryker Corporation · 1999
- Compositions and therapeutic methods using morphogenic proteins and stimulatory factors225US 5,916,870 AStryker Corporation · 1999
- Compositions and therapeutic methods using morphogenic proteins and stimulatory factors214US 5,854,207 AStryker Corporation · 1998
- Compositions and therapeutic methods using morphogenic proteins and stimulatory factors160US 6,048,964 AStryker Corporation · 2000
- Device, system and methods for the oral delivery of therapeutic compounds138US 8,734,429 B2Rani Therapeutics, LLC · 2014